Bangalore Bioinnovation Centre receives “Innovation Leadership Award”
Dr Jitendra Kumar, Managing Director of BBC said “It is an honour for team BBC to receive this award. It is great that the jury has looked into the institutions that have made the difference to the lives of others”
COVAXIN phase 2 study results & Phase-1 follow Up data
COVAXIN™ (BBV152) showed long-term antibody and T-cell memory responses (3-months after vaccination) in phase 1 volunteers, and tolerable safety outcomes with enhanced humoral & cell-mediated immune responses in the Phase 2 study.
Ocugen and Bharat Biotech to co-develop COVAXIN™, a whole-virion inactivated COVID-19 vaccine, for the US market
Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US. Builds upon the promising safety and immunogenicity data in the Phase 1 and Phase 2 trials. Vaccine candidate is an inactivated (“traditional”) type vaccine with potentially broad appeal
Karnataka aims to become $50 billion bioeconomy by 2025 - The Indian Express
The government released its first draft of the bio-economy report 2020 at the Bengaluru Tech Summit. While the report estimates the bio-economy of the state at USD 22.6 billion (Rs 1,67,240 crores) and growing at present, it is projected to USD 42 billion by 2025.